Which semaglutide is best for weight loss in the UK?

Why can't Ozempic or Rybelsus be used for weight loss?

Ozempic (semaglutide 0.5mg, 1mg, 2mg) and Rybelsus (semaglutide 3mg, 7mg, 14mg tablets) are both produced by Novo Nordisk and contain the same GLP-1 receptor agonist as Wegovy. The molecule is identical. The licences are not. The MHRA has authorised Ozempic and Rybelsus specifically for blood-sugar control in adults with type 2 diabetes, and that is the clinical evidence base they sit on. The NHS semaglutide medicine page explains the distinction clearly.

Prescribing either off-label for weight management without diabetes is a separate, legally permissible clinical decision, but it carries no manufacturer support, no structured titration pathway for this indication, and no price advantage over Wegovy. Reputable clinics do not offer this route routinely. If you have come across sellers offering Ozempic pens for weight loss without asking about your diabetes status, that is a red flag worth pausing on.

The short version: if weight management is your goal, only the Wegovy formulations were designed and licensed for it.

What does the evidence say about Wegovy's weight-loss results?

The Wegovy injection has the deeper evidence trail. The STEP 1 trial (68 weeks, adults with obesity or overweight and at least one weight-related condition, no diabetes) showed an average body-weight reduction of roughly 15% at the 2.4mg weekly maintenance dose, published in the New England Journal of Medicine. NICE recommended semaglutide for weight management under technology appraisal TA875, though NHS access through specialist services remains limited and waiting lists can be long.

The higher-dose 7.2mg injection, approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026, moved average weight loss to around 20.7% in trials over 72 weeks. That figure approaches the results seen with tirzepatide at its highest dose, narrowing a gap that once looked much wider. The 7.2mg pen is licensed for adults with a BMI of 30 or above only, a prescriber would confirm whether that pathway fits your situation.

The semaglutide and weight loss page goes deeper on the trial data if you want the full picture before a consultation.

Is the Wegovy tablet a realistic alternative to the injection?

For many people, yes. On 11 June 2026 the MHRA approved oral semaglutide co-formulated with an absorption enhancer as the first GLP-1 tablet licensed for weight management in the UK, the country was first in Europe to do so. The product is taken once daily, first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food, coffee or other oral medicines. No fridge needed: it stores at room temperature, which removes one practical barrier for people who travel frequently or simply find refrigerating medication awkward.

The OASIS 4 phase 3 trial (307 adults, 64 weeks, vs placebo) showed around 13.6% average weight loss regardless of adherence. Among participants who stayed fully adherent throughout, that figure rose to roughly 17%. Both numbers come from a well-designed randomised trial, and the difference between them reflects real-world behaviour, it is honest rather than alarming. Side effects were predominantly gastrointestinal, as with the injection, and generally mild to moderate.

If injections are the main thing putting you off, the tablet is worth exploring. A note on how to take semaglutide effectively covers both forms and what the evidence says about timing and consistency.

Which semaglutide form actually suits you, and how is that decided?

Honestly, this is a prescriber's call rather than a reader's. The licensed options differ in route of administration, dosing schedule, storage requirements, and the specific BMI and comorbidity thresholds they are approved against. Someone with a BMI of 28 and hypertension has a different eligibility picture from someone with a BMI of 35 and no other conditions. A person established on the 2.4mg injection who wants to switch to the tablet has a different starting point again, the SmPC guidance allows moving directly to the 25mg tablet dose after clinical review, without restarting from scratch.

For a sense of how the private route works, the semaglutide for weight loss overview sets out what clinical assessment involves and what to expect at each stage. If cost is part of your thinking, the where to buy Wegovy page covers pricing context and what any legitimate price should include.

At nume, consultations are reviewed the same day by a real prescriber, a named, GPhC-registered Independent Prescriber reads your answers, not a decision tree. If treatment is clinically appropriate, it is dispatched the same day and arrives the next working day via DPD, in plain packaging with nothing on the outside to hint at what is inside. Check your eligibility to start that process.